Abst #1473 evaluated association of SJC in PROs from 2 Bimekizumab trials (bDMARD naïve vs TNFi-IR) -bDMARD naïve had less SJC at baseline -In both groups, pts w lower SJC had sustained improvement in pain and fatigue over time. #ACR24 @RheumNow https://t.co/zwxsSbga7c

• https://x.com/AdelaCastro222/status/1858180798488424715/photo/1

What do current national/international rheumatology association guidelines say about perioperative discontinuation of biologics? it's highly, highly variable no wonder people get confused! #ACR24 ABST1037 @CatherineL_Hill @RheumNow https://t.co/cmJ3qKU1QT

• https://x.com/drdavidliew/status/1858182160169242882/photo/1

Late-onset asthma but earlier EGPA diagnosis? Abstract 1604 used IQVIA data to develop a machine learning model for better EGPA dx. Key predictors included eosinophilia, asthma, chronic sinusitis, multiple CXRs, skin biopsies, and GC prescriptions. @RheumNow #ACR24

#1477 🔬Zasocitinib (TYK-2i) shows promise in phase IIb RCT ➡️n=290, randomised to PBO, 5/15/30mg gps 💥30mg group 📉 Rapid skin improvement @ Wk 2 ➡️Wk 12 PASI:~2X placebo (-2.5;p=0.004) 🛟Well tolerated ⬆️MDA (28 v. 12.5% p<0.05) promise for other PsA domains #ACR @RheumNow https://t.co/5GusMlVkQ4

• https://x.com/CaoilfhionnMD/status/1858180043656073432/photo/1

New agent on the block: Bimekizumab IL-17A/F inhibitor Promising clinical data in SpA - what about imaging findings? Dramatic reductions in MRI activity at SI joints seen in BKZ pt, esp when compared to trajectory of PBO pt before cross-over @RheumNow #ACR24 Abst #1757 https://t.co/ACLJx5XkyN

• https://x.com/Dr_Brian_MD/status/1858168067844383139/photo/1

Appreciate the conversation with Dr Ana-Maria Orbai @jhrheumatology on abstract#0600 on bimekizumab PRO data https://t.co/86J4HWKeIv @RheumNow #ACR24 https://t.co/QYqj5rKHIH

• Bimekizumab in PsA Showed Sustained Reductions in Disease Impact
• https://twitter.com/ericdeinmd/status/1857849021110354277

GILZ is a negative regulator of the GC receptor, a potential steroid sparer target. Dr. Miceli et al identified an E3 ligase of GILZ "E3-X" where deficiency leads to ⬆️ GILZ & ⬇️ inflammation. More studies needed but a promising steroid sparer option. @Rheumnow #ACR24 abs1646 https://t.co/GuVMkgOTXT

• https://x.com/RHEUMarampa/status/1858169289213120842/photo/1
• https://x.com/RHEUMarampa/status/1858169289213120842/photo/1

Navigating Positive ANA: Leveraging AI for better triage Abstract 1526: Markus et al. developed a machine learning model to predict progression to SLE, utilizing diagnoses, meds, procedures, and labs collected 2 years before and 5 years after +ANA. @RheumNow #ACR24 https://t.co/2zzSH8Pb0e

• https://x.com/AkhilSoodMD/status/1858171487569547757/photo/1
• https://x.com/AkhilSoodMD/status/1858171487569547757/photo/1

#1474 🔬Severe PsA? Guselkumab (GUS) has promise! ➡️In bionaive pts with severe disease activity, GUS v. PBO resulted in: 🔴73% improvement in joints 🔴53% lower disease activity 🔴63% better PtGA by 2 years ➡️Rapid results by W2, sustained through W100. #ACR @RheumNow

Impressive Plenary @andreafava just finished Novel urine protein panel id 12 proteins that predict NIH activity on renal bx better than existing options Improving at 3 mos predicts response at 1 year Could reduce biopsies / modulate tx! #ACR24 @RheumNow Abstr#1642 #ACRbest https://t.co/Gi6u6hAGzj

• https://x.com/EBRheum/status/1858155100948124140/photo/1
• https://x.com/EBRheum/status/1858155100948124140/photo/1